entecavir (Baraclude)

Advice

following a full submission

entecavir (Baraclude®) is not recommended for use within NHS Scotland.

Indication under review: treatment of chronic hepatitis B virus (HBV) infection in adults with decompensated liver disease.

Entecavir demonstrated a superior virological response in adults with chronic HBV and decompensated liver disease compared with another nucleoside/nucleotide analogue. However there is no comparative evidence versus the relevant comparator.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.